Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

59
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
59
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

39
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
39
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

43
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
43
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

648
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
648
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

87
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
87
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

295
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
295

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

ObesityWeek® 2025-Reflecting on an Exciting Time in Obesity Research and Treatment.

Obesity (Silver Spring, Md.)·2026
Same author

Artificial Intelligence-Based Approach for Automated Gonad Volume Quantification Using Magnetic Resonance Imaging in Healthy Adolescents Across Puberty.

Diagnostics (Basel, Switzerland)·2026
Same author

<i>Blautia wexlerae</i> Transforms Dietary Fatty Acids to Activate Enteroendocrine Signaling and Improve Metabolic Health in Mice and Humans.

bioRxiv : the preprint server for biology·2026
Same author

Prevention of Excess Weight Gain Among Adolescent Military-Dependents at High Risk for Obesity.

Obesity (Silver Spring, Md.)·2026
Same author

Effects of Intraperitoneal Colchicine on the Metabolic Consequences of High Fat Diet-Induced Obesity in Mice.

Endocrine, metabolic & immune disorders drug targets·2026
Same author

The Physiology Of the WEight Reduced State (POWERS) study: design and rationale for assessment of food intake, physical activity and other behavioral constructs.

International journal of obesity (2005)·2026

Video Experimental Relacionado

Updated: Nov 1, 2025

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

544

Los avances en la farmacoterapia para la obesidad

Susan Z Yanovski1, Jack A Yanovski2

  • 1Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland.

JAMA
|June 23, 2021
PubMed
Resumen

No abstract available in PubMed .

Más Videos Relacionados

An Acupoint Catgut-embedding Therapy for Treating Obesity
04:50

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

749
Control of Eating Behavior Using a Novel Feedback System
04:48

Control of Eating Behavior Using a Novel Feedback System

Published on: May 8, 2018

11.2K

Videos de Experimentos Relacionados

Last Updated: Nov 1, 2025

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

544
An Acupoint Catgut-embedding Therapy for Treating Obesity
04:50

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

749
Control of Eating Behavior Using a Novel Feedback System
04:48

Control of Eating Behavior Using a Novel Feedback System

Published on: May 8, 2018

11.2K